ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Consolidated Issue listed on NASDAQ Global Market

18.15USD
1 Jul 2013
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$18.15
Open
$18.38
Day's High
$18.96
Day's Low
$17.95
Volume
2,528,447
Avg. Vol
4,466,475
52-wk High
$20.09
52-wk Low
$1.42

ACAD.O

Chart for ACAD.O

About

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class... (more)

Overall

Beta: 2.62
Market Cap (Mil.): $1,597.25
Shares Outstanding (Mil.): 88.00
Dividend: --
Yield (%): --

Financials

  ACAD.O Industry Sector
P/E (TTM): -- 34.05 33.02
EPS (TTM): -0.34 -- --
ROI: -35.35 -2.50 19.07
ROE: -42.68 -3.10 20.00
Search Stocks

Latest News about ACAD.O

Acadia says data from Parkinson's trial enough to file for approval

- Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, and that it would not need to conduct an additional trial as planned earlier.

11 Apr 2013

BRIEF-ACADIA Pharma up in premarket after phase III pimavanserin study data

NEW YORK, March 21 - ACADIA Pharmaceuticals Inc : * Pharma up 6.5 percent to $7.08 in premarket after phase III pimavanserin study data

21 Mar 2013
» More ACAD.O News

Competitors

  Price Change
Pfizer Inc. (PFE.N) $27.78 -0.23
Johnson & Johnson (JNJ.N) $86.63 +0.77
AstraZeneca plc (AZN.L) 3,156.50p +5.50
Eli Lilly & Co. (LLY.N) $50.16 +1.04
Bristol Myers Squibb Co. (BMY.N) $44.82 +0.13
Bristol Myers Squibb Co. (BMYMP.PK) -- --
Allergan, Inc. (AGN.N) $83.90 -0.34

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Thomson Reuters Stock Report - ACADIA PHARMACEUTICALS, INC. (ACAD-O)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Market Edge Equity Research Report
Provider: Market Edge
$10.00
Buy
ACADIA Pharmaceuticals
Provider: S&P Capital IQ Quantitative Report
$69.00
Buy
ACADIA PHARMACEUTICALS INC (ACAD) 12-months forecast
Provider: Pechala's Reports
$15.00
Buy
ACADIA Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research
Search Stocks